(Q42618816)

English

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

scientific article published on 24 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study (English)

1 reference

Europe PubMed Central

3 November 2017

1 reference

based on heuristic

inferred from title

inflammatory breast cancer

1 reference

based on heuristic

inferred from title

Thomas Bachelot

5

object named as

Thomas Bachelot

1 reference

Europe PubMed Central

3 November 2017

author name string

Bella Kaufman

1

1 reference

Europe PubMed Central

3 November 2017

Maureen Trudeau

2

1 reference

Europe PubMed Central

3 November 2017

Ahmad Awada

3

1 reference

Europe PubMed Central

3 November 2017

Kimberly Blackwell

4

1 reference

Europe PubMed Central

3 November 2017

Vanessa Salazar

6

1 reference

Europe PubMed Central

3 November 2017

Michelle DeSilvio

7

1 reference

Europe PubMed Central

3 November 2017

Ronald Westlund

8

1 reference

Europe PubMed Central

3 November 2017

Tal Zaks

9

1 reference

Europe PubMed Central

3 November 2017

Neil Spector

10

1 reference

Europe PubMed Central

3 November 2017

Stephen Johnston

11

1 reference

Europe PubMed Central

3 November 2017

publication date

24 April 2009

1 reference

Europe PubMed Central

3 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

3 November 2017

10

1 reference

Europe PubMed Central

3 November 2017

581-588

1 reference

Europe PubMed Central

3 November 2017

6

1 reference

Europe PubMed Central

3 November 2017

Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Update on the management of inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory breast cancer: clinical progress and the main problems that must be addressed

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory breast cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Update on inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Her-2/neu and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in inflammatory breast cancer and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of inflammatory breast cancer (IBC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The medical treatment of inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year outcome after combined modality therapy for inflammatory breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Common side effects of anti-EGFR therapy: acneform rash

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70087-7

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42618816&oldid=1963256600"